Trial Profile

A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surufatinib (Primary)
Indications Gastric cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
Focus Adverse reactions
Sponsors Hutchison MediPharma

Most Recent Events

13 Sep 2022 Results from NCT02267967, NCT02588170, NCT02589821; assessing whether radiomics-based machine learning model could predict treatment responses in patients with advanced NET, presented at the 47th European Society for Medical Oncology Congress
21 Feb 2018 Status changed from active, no longer recruiting to completed.
19 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com